“A+H”再添双巨头！宁德时代、恒瑞医药相继通过港交所聆讯

Group 1: CATL (宁德时代) - CATL is a global leader in the innovation of new energy technology, primarily engaged in the research, production, and sales of power batteries and energy storage batteries [1][2] - The company has maintained the number one global market share in power batteries for eight consecutive years, with a projected market share of 37.9% in 2024; it also ranks first in energy storage batteries for four years, with a projected market share of 37% in 2024 [1][2] - As of the end of 2024, CATL has established six R&D centers and thirteen battery manufacturing bases globally, serving 64 countries and regions, with over 1.7 million electric vehicles equipped with CATL batteries [1][2] Group 2: Financial Performance of CATL - CATL's revenue for 2022, 2023, and 2024 is projected to be RMB 328.59 billion, RMB 400.92 billion, and RMB 362.01 billion, respectively, with net profits of RMB 33.46 billion, RMB 47.34 billion, and RMB 55.30 billion [2] - In 2024, 30.5% of the company's revenue is expected to come from overseas markets [2] Group 3: Hengrui Medicine (恒瑞医药) - Hengrui Medicine, founded in the early 1970s, focuses on multiple therapeutic areas, including oncology, metabolism, cardiovascular diseases, immunology, and neuroscience, with over 110 commercialized drugs [3][4] - The company's revenue for 2022, 2023, and 2024 is projected to be RMB 21.27 billion, RMB 22.82 billion, and RMB 27.98 billion, respectively, with a compound annual growth rate exceeding 14%, significantly higher than the global pharmaceutical market's growth rate of about 4% [3][4] - Hengrui has established 14 global R&D centers and has initiated over 20 overseas clinical trials, with products commercialized in over 40 countries [4] Group 4: Strategic Initiatives of Hengrui Medicine - The company has a pipeline of over 90 candidate new molecular entity innovative drugs and has engaged in 14 licensing transactions with global partners since 2018, totaling approximately USD 14 billion [4] - Hengrui Medicine emphasizes a "dual-driven strategy" of "innovation + internationalization," positioning internationalization as a key focus for growth [4][5]